These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18653222)

  • 1. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature.
    Schwarz TF; Leo O
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S1-10. PubMed ID: 18653222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
    McKeage K; Romanowski B
    BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
    McKeage K; Romanowski B
    Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.
    Schwarz TF; Spaczynski M; Schneider A; Wysocki J; Galaj A; Perona P; Poncelet S; Zahaf T; Hardt K; Descamps D; Dubin G;
    Vaccine; 2009 Jan; 27(4):581-7. PubMed ID: 19022320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
    Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
    BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
    Schwarz TF; Spaczynski M; Schneider A; Wysocki J; Galaj A; Schulze K; Poncelet SM; Catteau G; Thomas F; Descamps D
    Hum Vaccin; 2011 Sep; 7(9):958-65. PubMed ID: 21892005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.
    Schwarz T; Spaczynski M; Kaufmann A; Wysocki J; Gałaj A; Schulze K; Suryakiran P; Thomas F; Descamps D
    BJOG; 2015 Jan; 122(1):107-18. PubMed ID: 25208608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age.
    Schwarz TF; Galaj A; Spaczynski M; Wysocki J; Kaufmann AM; Poncelet S; Suryakiran PV; Folschweiller N; Thomas F; Lin L; Struyf F
    Cancer Med; 2017 Nov; 6(11):2723-2731. PubMed ID: 28984053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.
    Szarewski A; Poppe WA; Skinner SR; Wheeler CM; Paavonen J; Naud P; Salmeron J; Chow SN; Apter D; Kitchener H; Castellsagué X; Teixeira JC; Hedrick J; Jaisamrarn U; Limson G; Garland S; Romanowski B; Aoki FY; Schwarz TF; Bosch FX; Harper DM; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Int J Cancer; 2012 Jul; 131(1):106-16. PubMed ID: 21858807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.
    Zhu FC; Li CG; Pan HX; Zhang YJ; Bi D; Tang HW; Datta S
    Chin J Cancer; 2011 Aug; 30(8):559-64. PubMed ID: 21801604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
    Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
    Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
    Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
    J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
    J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.
    Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F
    Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.